A rapid pathway for diagnosing heart attacks in the emergency department (ED) was as safe as a slower pathway but neither reduced the length of time patients spent in the ED nor increased direct discharge from the ED. These were the main findings of the PRESC1SE-MI trial and an independent participant data meta-analysis of all randomized trials presented in a Hot Line session at ESC Congress 2026. The findings were published simultaneously in The Lancet.
Rapid Testing for Heart Attacks: No Impact on Emergency Department Stay
The PRESC1SE-MI trial found that a rapid diagnostic pathway for heart attacks in emergency departments is as safe as a traditional method but does not shorten patient stay or increase discharges. This study, presented at ESC Congress 2026 and published in The Lancet, is relevant for healthcare practices in Iran.
👥 Key Players
📰 What Happened
The PRESC1SE-MI trial evaluated a rapid diagnostic pathway for heart attacks in emergency departments, finding it as safe as traditional methods but ineffective in reducing patient stay or increasing discharges. These results were presented at ESC Congress 2026 and published in The Lancet.
- The rapid diagnostic pathway did not shorten emergency department stays.
- The study was part of a larger meta-analysis of randomized trials.
💡 Why It Matters
📚 Background
Heart attacks are a leading cause of death, making timely diagnosis crucial. Understanding different diagnostic pathways can help improve patient outcomes.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%